About
About Life Science Dx
Life Science Dx Consulting helps diagnostics, precision medicine, life science tools, and healthcare technology companies turn complex science into market adoption and commercial growth.
The firm works with organizations developing clinical diagnostics, AI-enabled healthcare platforms, companion diagnostics, molecular and NGS-based tests, digital pathology solutions, specialty therapeutics, and clinical laboratory business models.
Founder
Founded by Robert Carlson
Robert Carlson is a diagnostics and life sciences commercial executive with more than 30 years of combined scientific, commercial, business development, and operating leadership experience. He founded Life Science Dx Consulting to help companies translate complex science, clinical insight, and differentiated technology into commercially executable growth strategies.
Robert founded Life Science Dx in 2019 following his tenure as Chief Commercial Officer of Prometheus Laboratories, where he led a commercial organization of approximately 185 employees and held responsibility for more than $300 million in annual revenue across diagnostics and specialty pharmaceuticals.
His background spans diagnostic assay development, life science tools, companion diagnostics, CLIA/LDT commercialization, specialty diagnostics, digital pathology, AI-enabled healthcare, strategic partnerships, corporate development, reimbursement alignment, and executive commercial leadership.
Purpose
Why Life Science Dx Exists
Diagnostics, precision medicine, and healthcare technology companies often reach a point where the science is sound, the clinical rationale is clear, and the technology is differentiated — but the path to commercial adoption remains uncertain. The questions that determine whether a product succeeds in the market are rarely answered by the science alone.
- Who is the economic customer?
- What clinical decision does the product change?
- What evidence is needed for adoption and reimbursement?
- How does the test, platform, or product fit into clinical workflow?
- What commercial model is realistic for the market?
- What sales, marketing, access, and partnership infrastructure is required?
- What must be true for the business to scale?
Life Science Dx helps companies answer these questions before commercial execution becomes expensive, misaligned, or difficult to correct.
Approach
Commercial Strategy Grounded in Operating Experience
Life Science Dx is built around practical execution, not theoretical strategy. The work is informed by hands-on experience across diagnostic commercialization, CLIA and LDT business models, companion diagnostics, GI diagnostics, oncology diagnostics, AI-enabled digital pathology, NGS and molecular diagnostics, life science tools, specialty therapeutics, strategic partnerships, reimbursement strategy, market access, salesforce design, CRM, forecasting, cadence, and revenue execution. The goal is to help companies move from promising science to a commercially executable plan.
Experience
Selected Client & Company Experience
Life Science Dx Consulting draws on practical commercialization experience across diagnostics, precision medicine, AI-enabled healthcare, life science tools, companion diagnostics, specialty therapeutics, and clinical laboratory markets.
Selected Consulting & Advisory Relationships
Ibex Medical Analytics
AI-enabled digital pathology software for cancer detection and tissue morphology assessment.
Genece Health
Sequencing-based diagnostics venture focused on lung nodule classification.
Mithrl AI
AI and NLP platform for clinical trial data analysis and evidence generation.
Precision Chemo
Therapeutics venture developing chemotherapy agents with companion diagnostic strategy.
Biomerica
Diagnostic Guided Therapy® platform for IBS and food-triggered chronic conditions. Also prior operating leadership experience.
Demeter Sciences
Biotechnology venture developing novel antibiotics from naturally occurring organisms.
Endpoint Health
Precision therapeutics and companion diagnostics company focused on immune-mediated disease.
Discovery Science Foundation
Nonprofit STEM education organization supporting hands-on science learning.
Prior Operating & Commercial Leadership Experience
Owlstone Medical / OMED Health
Breath Biopsy® and VOC-based diagnostics platform for cancer, GI, metabolic, and liver disease applications.
Prometheus Laboratories / Nestlé Health Science
Market-leading GI diagnostics and specialty pharmaceutical company; Nestlé Health Science Center of Excellence.
Dako / Agilent Technologies
Global leader in companion diagnostics, immunohistochemistry, molecular diagnostics, pathology instrumentation, and digital pathology.
Biomerica
CLIA-based Diagnostic Guided Therapy® company commercializing inFoods® IBS.
WaveSense
Hematology, oncology, and cytogenetics platform company commercializing EpiSep® cell isolation technology.
DakoCytomation
Flow cytometry instrumentation and clinical laboratory platform company.
Biacore / GE Healthcare
Advanced SPR instrumentation platform for label-free molecular interaction analysis.
Hybritech / Beckman Coulter
Oncology diagnostics and immunodiagnostic research organization.
Company names reflect selected consulting, advisory, employment, and operating leadership experience. Use does not imply current affiliation, endorsement, or sponsorship.
Engagement
How Life Science Dx Works
Life Science Dx supports leadership teams, founders, boards, investors, and commercial organizations through focused advisory projects, strategic assessments, interim commercial leadership, and fractional executive support. Engagements are scoped to produce clear decisions, practical recommendations, and commercially actionable next steps.
Engagements range from commercial strategy assessments and market opportunity evaluations to launch readiness planning, reimbursement alignment, partnership support, investor narrative refinement, and fractional or interim commercial leadership.
Contact
Need a commercial perspective on a diagnostic, precision medicine, or life science platform?
Life Science Dx can help evaluate the market opportunity, clarify the adoption pathway, pressure-test the commercial model, and define the next steps required for growth.